Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
White soft paraffin + cetomacrogol cream is a topical emollient formulation used to restore and maintain the skin barrier. It combines white soft paraffin (petrolatum), which acts as an occlusive agent to prevent transepidermal water loss, with cetomacrogol cream, a non-ionic emulsifying cream base. This formulation does not contain any pharmacologically active ingredients targeting specific biological receptors; instead, it functions purely as a physical barrier to hydrate the skin. In a randomized, double-blind, placebo-controlled clinical trial sponsored by Havenziekenhuis, this formulation was evaluated as the emollient-alone control arm in wet-wrap therapy (WWT) for pediatric patients aged 6 months to 10 years with severe atopic dermatitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on white soft paraffin + cetomacrogol cream.